The company’s study included 105 kids, ages 7 to 13.
Medtronic (NYSE:MDT) touted data today from an at-home pediatric study of its MiniMed 670G hybrid closed-loop diabetes management system.
The company’s study included 105 kids, ages 7 to 13, and found that patients spent more time in the target blood glucose range, had less glycemic variability and experienced less hypo- and hyperglycemia compared to baseline data. Data from the pediatric study was included as part of an application to the FDA, as Medtronic looks to expand MiniMed’s indication to include children between the ages of 7 and 13.
